文献速递肿瘤 PET/CT核素与放射性配体治疗

SMARCA4缺陷型低分化胆囊腺癌

SMARCA4-Deficient Poorly Differentiated Adenocarcinoma of the Gallbladder.
PubMed 文献 · Clin Nucl Med · 2024-04-08

本文报告一例64岁女性SMARCA4缺陷型低分化胆囊腺癌,影像显示胆囊大肿瘤侵犯肝脏并伴腹水和胸腔积液,活检确诊为低分化腺癌伴SMARCA4缺陷(cT3N2M1,cStage IV),化疗无效并导致肿瘤进展,患者9个月后死亡。本文结合影像学表现(包括FDG PET)对该病进行报道。

要点

  • SMARCA4缺陷是肿瘤中发现的基因突变,近年受到关注。
  • 本例为胆囊低分化腺癌伴SMARCA4缺陷,分期cT3N2M1、cStage IV。
  • 本例化疗无效并出现肿瘤进展,患者9个月后死亡。

核心结论

  • 本文报告一例SMARCA4缺陷型低分化胆囊腺癌,并结合包括FDG PET在内的影像学表现进行描述。

研究设计与样本

  • 病例报告:一例64岁女性患者,因进食时胸痛转诊至本院。

主要发现

  • 影像显示胆囊大肿瘤侵犯肝脏,伴腹水和胸腔积液。
  • 活检确诊为低分化腺癌伴SMARCA4缺陷(cT3N2M1,cStage IV)。
  • 化疗无效并导致肿瘤进展,患者9个月后死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 64-year-old woman presented with chest pain while eating and was referred to our hospital. Physical examination revealed abdominal distension, tenderness, and lower-extremity edema. Imaging revealed a large gallbladder tumor infiltrating the liver, with ascites and pleural effusion. A biopsy confirmed a poorly differentiated adenocarcinoma with SMARCA4 deficiency (cT3N2M1, cStage IV). Chemotherapy was ineffective and led to tumor progression. The patient died 9 months later. Recently, attention has been paid to SMARCA4 deficiency, which is a genetic mutation found in tumors. Here, we report on poorly differentiated adenocarcinomas of the gallbladder based on imaging findings, including FDG PET.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Koyasu S, Sugimoto A, Matsubara J, et al. SMARCA4-Deficient Poorly Differentiated Adenocarcinoma of the Gallbladder. Clin Nucl Med. 2024. PMID: 38598517. doi:10.1097/RLU.0000000000005217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。